This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mayer, L. D. Articles by Cullis, P. R. Search for Related Content PubMed PubMed Citation Articles by Mayer, L. D. Articles by Cullis, P. R.

Liposomal Vincristine Preparations Which Exhibit Decreased Drug Toxicity and Increased Activity against Murine L1210 and P388 Tumors¹

Department of Biochemistry, University of British Columbia, Vancouver, British Columbia V6T 1W5 [L. D. M., M. B. B., H. L., P. R. C.], and The Canadian Liposome Co., Ltd., North Vancouver, British Columbia V7M 1A5 [L. D. M., M. B. B., D. M., P. R. C.], Canada

The toxicity and antitumor activity of liposomal vincristine preparations have been examined. Vincristine was encapsulated inside egg phosphatidylcholine (EPC)/cholesterol (55/45, mol/mol) and distearoylphosphatidylcholine (DSPC)/cholesterol (55/45, mol/mol) vesicles utilizing transmembrane pH gradient (inside acidic) drug uptake processes. Trapping efficiencies approaching 100% were achieved for this procedure using drug:lipid ratios as high as 0.2:1 (w/w). Although both EPC/cholesterol and DSPC/cholesterol liposomal systems yielded high trapping efficiencies, DSPC/cholesterol vesicles exhibited superior drug retention properties. This ability to retain entrapped vincristine was related to maintenance of the transmembrane pH gradient as well as the membrane permeability properties. Thirty-day dose-response survival studies in mice indicated that vincristine encapsulated in DSPC/cholesterol liposomes was less toxic than free drug. The 50% lethal dose of 1.9 mg/kg in CD-1 mice observed for free vincristine increased to 4.8 mg/kg upon administration of the drug in liposomal form. Liposome encapsulation of vincristine also enhanced the antitumor activity against murine P388 and L1210 lymphocytic leukemia models. This resulted from increased efficacy for liposomal vincristine at doses equal to free drug (liposomal/free drug median survival times > 1.0) as well as the ability to administer increased doses of liposomal vincristine. The combined effects of decreased toxicity and increased antitumor efficacy of liposomal vincristine over free drug suggest significant clinical utility of appropriate liposomal vincristine systems.

¹ This work was supported by the National Cancer Institute of Canada and The Liposome Co., Inc. (Princeton, NJ). P. R. C. is a Canadian Medical Research Council scientist.

Received 6/ 6/89. Revised 8/21/89. Revised 10/18/89. Accepted 10/30/89.

This article has been cited by other articles:

				P. Sapra and T. M. Allen Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes Clin. Cancer Res., April 1, 2004; 10(7): 2530 - 2537. [Abstract] [Full Text] [PDF]

				P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]

				S. A. Abraham, C. McKenzie, D. Masin, R. Ng, T. O. Harasym, L. D. Mayer, and M. B. Bally In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading Clin. Cancer Res., January 15, 2004; 10(2): 728 - 738. [Abstract] [Full Text] [PDF]

				R. Krishna, M. S. Webb, G. St. Onge, and L. D. Mayer Liposomal and Nonliposomal Drug Pharmacokinetics after Administration of Liposome-Encapsulated Vincristine and Their Contribution to Drug Tissue Distribution Properties J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1206 - 1212. [Abstract] [Full Text] [PDF]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]

				M. S. Webb, N. L. Boman, D. J. Wiseman, D. Saxon, K. Sutton, K. F. Wong, P. Logan, and M. J. Hope Antibacterial Efficacy against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation Antimicrob. Agents Chemother., January 1, 1998; 42(1): 45 - 52. [Abstract] [Full Text]

				M. J. Parr, D. Masin, P. R. Cullis, and M. B. Bally Accumulation of Liposomal Lipid and Encapsulated Doxorubicin in Murine Lewis Lung Carcinoma: The Lack of Beneficial Effects by Coating Liposomes with Poly(ethylene glycol) J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1319 - 1327. [Abstract] [Full Text]